[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-369363-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-369363-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","multi-targeted-not-gated-car-t-cells-as-a-strategy-to-protect-normal-lineages-for-blood-cancer-therapy-read-online-free","Multi-targeted, NOT gated CAR-T cells as a strategy to protect normal lineages for blood cancer therapy - read online free","","Multi-targeted, NOT gated CAR-T cells are presented as a strategy to protect normal blood lineages while treating blood cancers. Current CAR-T therapies are constrained by on-target, off-tumor toxicity because many established targets are also expressed on normal hematopoietic cells, and by relapse driven by target-antigen loss. The study applies a NOT gated Tmod™ system to improve therapeutic selectivity in blood cancer, demonstrating designs that can combine targeting of 2–4 antigens using activating receptors for CD33 and CD43 and inhibitory receptors for CD16b (FCGR3B) and CLEC9A. Results highlight the modularity of the approach and extend its rationale beyond solid tumors.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/multi-targeted-not-gated-car-t-cells-as-a-strategy-to-protect-normal-lineages-for-blood-cancer-therapy-read-online-free/369363/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/multi-targeted-not-gated-car-t-cells-as-a-strategy-to-protect-normal-lineages-for-blood-cancer-therapy-read-online-free/369363.png","ImageObject",300,407,{"name":42,"@type":43},"Ophelia","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are current CAR-T therapies difficult to apply safely in blood cancers like AML?","Question",{"text":63,"@type":64},"Many common blood cancer targets are also expressed on normal hematopoietic cells, causing on-target, off-tumor toxicity. Target-antigen loss can also drive relapse.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What is the NOT gated Tmod™ system used in this study?",{"text":68,"@type":64},"The study applies a technology called Tmod™, described as a NOT gated system, to address therapeutic selectivity for blood cancer cells.",{"name":70,"@type":61,"acceptedAnswer":71},"Which antigens and receptor types are used in the designed Tmod cells?",{"text":72,"@type":64},"The work describes activating receptors targeting CD33 and CD43, and inhibitory receptors targeting CD16b (FCGR3B) and CLEC9A to distinguish normal blood cells from most blood cancers.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},369363,1790801450,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},7971461741311,"https://ap-avatar.wpscdn.com/avatar/74000253aff267980c6?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779345379180704826","TYPE Original Research PUBLISHED 21 March 2025  \nDOI 10.3389/fimmu.2025.1493329  \nOPEN ACCESS  \nEDITED BY  \nJamie Berta Spangler,  \nJohns Hopkins University, United States  \nREVIEWED BY  \nAli Roghanian,  \nUniversity of Southampton, United Kingdom Frederic Thalheimer,  \nPaul-Ehrlich-Institut (PEI), Germany  \n*CORRESPONDENCE  \nAlexander Kamb  \n [akamb@a2biotherapeutics.com](akamb@a2biotherapeutics.com)  \nRECEIVED 09 September 2024  \nACCEPTED 21 February 2025  \nPUBLISHED 21 March 2025  \nCITATION  \nDiAndreth B, Nesterenko PA, Winters AG, Flynn AD, Jette CA, Suryawanshi V, Shafaattalab S, Martire S, Daris M, Moore E, Elshimali R, Gill T, Riley TP, Miller S, Netirojjanakul C, Hamburger AE and Kamb A (2025) Multi-targeted, NOT gated CAR-T cells as a strategy to protect normal lineages for blood cancer therapy.  \nFront. Immunol. 16:1493329 .  \ndoi: 10.3389/fimmu.2025.1493329  \nCOPYRIGHT  \n© 2025 DiAndreth, Nesterenko, Winters, Flynn, Jette, Suryawanshi, Shafaattalab, Martire, Daris, Moore, Elshimali, Gill, Riley, Miller, Netirojjanakul, Hamburger and Kamb. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nMulti-targeted, NOT gated CAR-T cells as a strategy to protect normal lineages for blood cancer therapy  \nBreanna DiAndreth, Pavlo A. Nesterenko, Aaron G. Winters, Aaron D. Flynn, Claudia A. Jette, Vasantika Suryawanshi, Sanam Shafaattalab, Sara Martire, Mark Daris, Elizabeth Moore, Ryan Elshimali, Tanveer Gill, Timothy P. Riley, Sara Miller, Chawita Netirojjanakul, Agnes E. Hamburger  \nand Alexander Kamb*  \nA2 Biotherapeutics Discovery Research, Agoura Hills, CA, United States  \nIntroduction: Despite advances in treatment of blood cancers, several—including acute myeloid leukemia (AML)—continue to be recalcitrant. Cell therapies based on chimeric antigen receptors (CARs) have emerged as promising approaches for blood cancers. However, current CAR-T treatments suffer from on-target, off-tumor toxicity, because most familiar blood cancer targets are also expressed in normal lineages. In addition, they face the common problem of relapse due to target-antigen loss. Cell therapeutics engineered to integrate more than one signal, often called logic-gated cells, can in principle achieve greater selectivity for tumors.  \nMethods: We applied such a technology, a NOT gated system called Tmod™ that is being developed to treat solid-tumor patients, to the problem of therapeutic selectivity for blood cancer cells.  \nResults: Here we show that Tmod cells can be designed to target 2-4 antigens to provide different practical and conceptual options for a blood cancer therapy: (i) mono-and bispeciﬁc activating receptors that target CD33, a well-known AML antigen expressed on the majority of AML tumors (as well as healthy myeloid cells) and CD43 (SPN), an antigen expressed on many hematopoietic cancers (and normal blood lineages); and (ii) mono-and bispeciﬁc inhibitory receptors that target CD16b (FCGR3B) and CLEC9A, antigens expressed on key normal blood cells but not on most blood cancers.  \nDiscussion: These results further demonstrate the robust modularity of the Tmod system and generalize the Tmod approach beyond solid tumors.  \nKEYWORDS  \nCAR-T cells, CD33, CD16, SPN, AML, LIR-1 (LILRB1), logic gate, blood cancer  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \n1 Introduction  \nCertain blood cancers such as AML are deadly diseases, with no broadly effective therapies other than chemotherapy preconditioning combined with stem cell transplant (1, 2) . One of the fundamental challenges is the lack of genes expressed uniquely in AML and o","cbCaiqQRy8gH60Pc","https://ap.wps.com/l/cbCaiqQRy8gH60Pc","pdf",8210858,13,"English","# Introduction\n# Methods\n# Results\n# Discussion\n# Keywords","[{\"question\":\"Why are current CAR-T therapies difficult to apply safely in blood cancers like AML?\",\"answer\":\"Many common blood cancer targets are also expressed on normal hematopoietic cells, causing on-target, off-tumor toxicity. Target-antigen loss can also drive relapse.\"},{\"question\":\"What is the NOT gated Tmod™ system used in this study?\",\"answer\":\"The study applies a technology called Tmod™, described as a NOT gated system, to address therapeutic selectivity for blood cancer cells.\"},{\"question\":\"Which antigens and receptor types are used in the designed Tmod cells?\",\"answer\":\"The work describes activating receptors targeting CD33 and CD43, and inhibitory receptors targeting CD16b (FCGR3B) and CLEC9A to distinguish normal blood cells from most blood cancers.\"}]","Multi-targeted, NOT gated CAR-T cells as a strategy to protect normal lineages for blood cancer therapy - read online free | PDF",1790182249,33,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/09dae6437b953fba68578320ffec0c4b.webp",983,1389,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4022497d214ea6a558365c19f59dfaa6.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0c094e8325015afdbb21e1de57353415.webp",981,1386,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/475ef8548cb990a12472eeea115ef4dc.webp",980,1385]